GB1107

**GB1107** is a potent, selective, orally active small molecule inhibitor of galectin-3 (Gal-3), a pro-fibrotic β-galactoside-binding lectin implicated in fibrosis and cancer progression, with a Kd of 37 nM for human Gal-3 and >1000-fold selectivity over other galectins. It demonstrates efficacy in preclinical models by attenuating liver fibrosis in CCl4-induced mice (reducing transaminases, Gal-3 levels, and collagen deposition via reversal of fibrosis-related gene expression), inhibiting lung adenocarcinoma growth and metastasis, suppressing anoikis resistance and invasion in thyroid cancer cells via AKT/β-catenin pathway modulation, and enhancing anti-tumor immunity through M1 macrophage polarization, CD8+ T cell infiltration, and synergy with PD-L1 inhibitors. Its chemical structure is (2R,3R,4S,5R,6R)-2-(3,4-dichlorophenyl)sulfanyl-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)triazol-1-yl)oxane-3,5-diol (CAS 1978336-61-6).[1][3][4][6][7]